Established Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2015, 53216-53220 [2014-21280]

Download as PDF 53216 Federal Register / Vol. 79, No. 173 / Monday, September 8, 2014 / Notices equipment manufacturers, separation system designers, and end users. Patricia A. Brink, Director of Civil Enforcement, Antitrust Division. [FR Doc. 2014–21286 Filed 9–5–14; 8:45 am] BILLING CODE P DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA–393] Established Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2015 Drug Enforcement Administration (DEA), Department of Justice (DOJ). ACTION: Notice. AGENCY: This notice establishes the initial 2015 aggregate production quotas for controlled substances in schedules I and II of the Controlled Substances Act (CSA) and the assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. DATES: Effective date: Effective September 8, 2014. FOR FURTHER INFORMATION CONTACT: Imelda Paredes, Executive Assistant, Office of Diversion Control, Drug Enforcement Administration, 8701 Morrissette Drive, Springfield, VA 22152, Telephone: (202) 598–6812. SUPPLEMENTARY INFORMATION: rmajette on DSK2TPTVN1PROD with NOTICES SUMMARY: Legal Authority The Drug Enforcement Administration (DEA) implements and enforces titles II and III of the Comprehensive Drug Abuse Prevention and Control Act of 1970, as amended. Titles II and III are referred to as the ‘‘Controlled Substances Act’’ and the ‘‘Controlled Substances Import and Export Act,’’ respectively, and are collectively referred to as the ‘‘Controlled Substances Act’’ or the ‘‘CSA’’ for the purpose of this action. 21 U.S.C. 801–971. The DEA publishes the implementing regulations for these statutes in title 21 of the Code of Federal Regulations (CFR), parts 1300 to 1321. The CSA and its implementing regulations are designed to prevent, detect, and eliminate the diversion of controlled substances and listed chemicals into the illicit market while providing for the legitimate medical, scientific, research, and industrial needs VerDate Mar<15>2010 15:14 Sep 05, 2014 Jkt 232001 of the United States. Controlled substances have the potential for abuse and dependence and are controlled to protect the public health and safety. Section 306 of the Controlled Substances Act (CSA) (21 U.S.C. 826) requires the Attorney General to establish aggregate production quotas for each basic class of controlled substance listed in schedules I and II and for ephedrine, pseudoephedrine, and phenylpropanolamine. This responsibility has been delegated to the Administrator of the DEA through 28 CFR 0.100(b). The Administrator, in turn, has redelegated this function to the Deputy Administrator, pursuant to 28 CFR pt. 0 subpt. R, App. Background The 2015 aggregate production quotas and assessment of annual needs represent those quantities of schedule I and II controlled substances and the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine to be manufactured in the United States in 2015 to provide for the estimated medical, scientific, research, and industrial needs of the United States, lawful export requirements, and the establishment and maintenance of reserve stocks. These quotas include imports of ephedrine, pseudoephedrine, and phenylpropanolamine but do not include imports of controlled substances for use in industrial processes. On July 2, 2014, a notice titled, ‘‘Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Proposed Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2015’’ was published in the Federal Register. 79 FR 37772. This notice proposed the 2015 aggregate production quotas for each basic class of controlled substance listed in schedules I and II and the 2015 assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. All interested persons were invited to comment on or object to the proposed aggregate production quotas and the proposed assessment of annual needs on or before August 1, 2014. Comments Received Five comments were received from DEA-registered manufacturers within the published comment period, offering comments on a total of 32 schedule I and II controlled substances. None of the respondents commented on the list I chemicals ephedrine, PO 00000 Frm 00055 Fmt 4703 Sfmt 4703 pseudoephedrine, and phenylpropanolamine. Commenters stated that the proposed aggregate production quotas for 1-(1,3Benzodioxol-5-yl)-2-(methylamino) butan-1-one (butylone), 1-(1,3Benzodioxol-5-yl)-2-(methylamino) pentan-1-one (pentylone), 2-(4-Bromo2,5-dimethoxyphenyl)-N-(2methoxybenzyl)ethanamine (25BNBOMe), 2-(4-Chloro-2,5dimethoxyphenyl)-N-(2methoxybenzyl)ethanamine (25CNBOMe), 2-(4-Iodo-2,5dimethoxyphenyl)-N-(2methoxybenzyl)ethanamine (25INBOMe), 2-(Methylamino)-1phenylpentan-1-one (pentedrone), 3Fluoro-N-methylcathinone (3-FMC), 4Fluoro-N-methylcathinone (4-FMC), 4Anilino-N-phenethyl-4-piperidine (ANPP), 4-Methyl-N-ethylcathinone (4MEC), 4-Methyl-apyrrolidinopropiophenone (4-MePPP), alpha-Pyrrolidinobutiophenone (aPBP), alpha-Pyrrolidinopentiophenone (a-PVP), amphetamine (for sale), codeine (for sale), dihydrocodeine, diphenoxylate, fentanyl, hydrocodone (for sale), hydromorphone, levorphanol, marihuana, morphine (for conversion), N-(1-Amino-3,3-dimethyl-1-oxobutan-2yl)-1-pentyl-1H-indazole-3-carboxamide (ADB-PINACA), N-(1-Amino-3-methyl1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1Hindazole-3-carboxamide (ABFUBINACA), naphthylpyrovalerone (naphyrone), oripavine, oxycodone (for conversion), oxymorphone (for conversion), oxymorphone (for sale), Quinolin-8-yl 1-(5-fluoropentyl)-1Hindole-3-carboxylate (5-Flouro-PB-22), and Quinolin-8-yl 1-pentyl-1H-indole-3carboxylate (PB-22) were insufficient to provide for the estimated medical, scientific, research, and industrial needs of the United States, export requirements, and the establishment and maintenance of reserve stocks. Determination of 2015 Aggregate Production Quotas and Assessment of Annual Needs In determining the 2015 aggregate production quotas and assessment of annual needs, the DEA has taken into consideration the above comments along with the factors set forth at 21 CFR 1303.11 and 21 CFR 1315.11, in accordance with 21 U.S.C. 826 (a), and other relevant factors, including the consideration of 2014 manufacturing quotas, current 2014 sales and inventories, 2015 export requirements, industrial use, additional applications for quotas, as well as information on research and product development requirements. Based on this information, the DEA has determined E:\FR\FM\08SEN1.SGM 08SEN1 Federal Register / Vol. 79, No. 173 / Monday, September 8, 2014 / Notices that adjustments to the proposed aggregate production quotas and assessment of annual needs for alfentanil, cocaine, codeine-N-oxide, codeine (for sale), dihydrocodeine, fentanyl, hydromorphone, levorphanol, marihuana, oripavine, oxymorphone (for conversion), and ephedrine (for sale) are warranted. This notice reflects those adjustments. Regarding 1-(1,3-Benzodioxol-5-yl)-2(methylamino)butan-1-one (butylone), 1-(1,3-Benzodioxol-5-yl)-2(methylamino)pentan-1-one (pentylone), 2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2methoxybenzyl)ethanamine (25BNBOMe), 2-(4-Chloro-2,5dimethoxyphenyl)-N-(2methoxybenzyl)ethanamine (25CNBOMe), 2-(4-Iodo-2,5dimethoxyphenyl)-N-(2methoxybenzyl)ethanamine (25INBOMe), 2-(Methylamino)-1phenylpentan-1-one (pentedrone), 3Fluoro-N-methylcathinone (3-FMC), 4Fluoro-N-methylcathinone (4-FMC), 4Anilino-N-phenethyl-4-piperidine (ANPP), 4-Methyl-N-ethylcathinone (4MEC), 4-Methyl-apyrrolidinopropiophenone (4-MePPP), alpha-Pyrrolidinobutiophenone (aPBP), alpha-Pyrrolidinopentiophenone (a-PVP), amphetamine (for sale), dihydrocodeine, fentanyl, hydromorphone, levorphanol, marihuana, N-(1-Amino-3,3-dimethyl-1oxobutan-2-yl)-1-pentyl-1H-indazole-3- carboxamide (ADB-PINACA), N-(1Amino-3-methyl-1-oxobutan-2-yl)-1-(4fluorobenzyl)-1H-indazole-3carboxamide (AB-FUBINACA), naphthylpyrovalerone (naphyrone), oxycodone (for conversion), oxymorphone (for sale), Quinolin-8-yl 1(5-fluoropentyl)-1H-indole-3carboxylate (5-Flouro-PB-22), and Quinolin-8-yl 1-pentyl-1H-indole-3carboxylate (PB-22), the DEA has determined that the proposed aggregate production quotas are sufficient to provide for the 2015 estimated medical, scientific, research, and industrial needs of the United States, export requirements, and the establishment and maintenance of reserve stocks. This notice finalizes these aggregate production quotas at the same amounts as proposed. As described in the previously published notice proposing the 2015 aggregate production quotas and assessment of annual needs, the DEA has specifically considered that inventory allowances granted to individual manufacturers may not always result in the availability of sufficient quantities to maintain an adequate reserve stock pursuant to 21 U.S.C. 826(a), as intended. See 21 CFR 1303.24. This would be concerning if a natural disaster or other unforeseen event resulted in substantial disruption to the amount of controlled substances available to provide for legitimate 53217 public need. As such, the DEA has included in all established schedule II aggregate production quotas, and certain schedule I aggregate production quotas, an additional 25% of the estimated medical, scientific, and research needs as part of the amount necessary to ensure the establishment and maintenance of reserve stocks. The resulting established aggregate production quota will reflect these included amounts. This action will not affect the ability of manufacturers to maintain inventory allowances as specified by regulation. The DEA expects that maintaining this reserve in certain established aggregate production quotas will mitigate adverse public effects if an unforeseen event results in the substantial disruption to the amount of controlled substances available to provide for legitimate public need, as determined by the DEA. The DEA does not anticipate utilizing the reserve in the absence of these circumstances. In accordance with 21 U.S.C. 826, 21 CFR 1303.11, and 21 CFR 1315.11, the Deputy Administrator hereby establishes the 2015 aggregate production quotas for the following schedule I and II controlled substances and the 2015 assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, expressed in grams of anhydrous acid or base, as follows: Established 2015 quotas (g) Basic class rmajette on DSK2TPTVN1PROD with NOTICES Schedule I (1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144) ........................................................................... [1-(5-Fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (XLR11) ............................................................. 1-(1,3-Benzodioxol-5-yl)-2-(methylamino)butan-1-one (butylone) ............................................................................................... 1-(1,3-Benzodioxol-5-yl)-2-(methylamino)pentan-1-one (pentylone) ........................................................................................... 1-(1-Phenylcyclohexyl)pyrrolidine ................................................................................................................................................ 1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201) .................................................................................................................... 1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694) ................................................................................................................... 1-[1-(2-Thienyl)cyclohexyl]piperidine ........................................................................................................................................... 1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200) ....................................................................................................... 1-Butyl-3-(1-naphthoyl)indole (JWH-073) .................................................................................................................................... 1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (SR-18 and RCS-8) ................................................................................... 1-Hexyl-3-(1-naphthoyl)indole (JWH-019) ................................................................................................................................... 1-Methyl-4-phenyl-4-propionoxypiperidine ................................................................................................................................... 1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM678) .............................................................................................................. 1-Pentyl-3-(2-chlorophenylacetyl)indole (JWH-203) .................................................................................................................... 1-Pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250) ................................................................................................................ 1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398) .................................................................................................................... 1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122) ................................................................................................................... 1-Pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19, RCS-4) ............................................................................................................ 1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081) ............................................................................................................... 2-(2,5-Dimethoxy-4-n-propylphenyl)ethanamine (2C-P) .............................................................................................................. 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E) ................................................................................................................... 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D) ................................................................................................................ 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N) .................................................................................................................. 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H) ............................................................................................................................... 2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36) ................ 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C) ................................................................................................................ 2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82) ................ 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I) ...................................................................................................................... VerDate Mar<15>2010 15:14 Sep 05, 2014 Jkt 232001 PO 00000 Frm 00056 Fmt 4703 Sfmt 4703 E:\FR\FM\08SEN1.SGM 08SEN1 15 15 15 15 10 45 45 15 45 45 45 45 2 45 45 45 45 45 45 45 30 30 30 30 30 15 30 15 30 53218 Federal Register / Vol. 79, No. 173 / Monday, September 8, 2014 / Notices Established 2015 quotas (g) rmajette on DSK2TPTVN1PROD with NOTICES Basic class 2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5) .......................... 2-(Methylamino)-1-phenylpentan-1-one (pentedrone) ................................................................................................................. 2,5-Dimethoxy-4-ethylamphetamine (DOET) .............................................................................................................................. 2,5-Dimethoxy-4-n-propylthiophenethylamine ............................................................................................................................. 2,5-Dimethoxyamphetamine ........................................................................................................................................................ 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2) ........................................................................................................ 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4) .................................................................................................. 3,4,5-Trimethoxyamphetamine .................................................................................................................................................... 3,4-Methylenedioxyamphetamine (MDA) .................................................................................................................................... 3,4-Methylenedioxymethamphetamine (MDMA) ......................................................................................................................... 3,4-Methylenedioxy-N-ethylamphetamine (MDEA) ..................................................................................................................... 3,4-Methylenedioxy-N-methylcathinone (methylone) .................................................................................................................. 3,4-Methylenedioxypyrovalerone (MDPV) ................................................................................................................................... 3-Fluoro-N-methylcathinone (3-FMC) .......................................................................................................................................... 3-Methylfentanyl ........................................................................................................................................................................... 3-Methylthiofentanyl ..................................................................................................................................................................... 4-Bromo-2,5-dimethoxyamphetamine (DOB) .............................................................................................................................. 4-Bromo-2,5-dimethoxyphenethylamine (2-CB) .......................................................................................................................... 4-Fluoro-N-methylcathinone (4-FMC) .......................................................................................................................................... 4-Methoxyamphetamine .............................................................................................................................................................. 4-Methyl-2,5-dimethoxyamphetamine (DOM) .............................................................................................................................. 4-Methylaminorex ........................................................................................................................................................................ 4-Methyl-N-ethylcathinone (4-MEC) ............................................................................................................................................ 4-Methyl-N-methylcathinone (mephedrone) ................................................................................................................................ 4-Methyl-a-pyrrolidinopropiophenone (4-MePPP) ....................................................................................................................... 5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol ................................................................................................. 5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP-47,497 C8-homolog) ................... 5-Methoxy-3,4-methylenedioxyamphetamine .............................................................................................................................. 5-Methoxy-N,N-diisopropyltryptamine .......................................................................................................................................... 5-Methoxy-N,N-dimethyltryptamine ............................................................................................................................................. Acetyl-alpha-methylfentanyl ......................................................................................................................................................... Acetyldihydrocodeine ................................................................................................................................................................... Acetylmethadol ............................................................................................................................................................................ Allylprodine .................................................................................................................................................................................. Alphacetylmethadol ...................................................................................................................................................................... alpha-Ethyltryptamine .................................................................................................................................................................. Alphameprodine ........................................................................................................................................................................... Alphamethadol ............................................................................................................................................................................. alpha-Methylfentanyl .................................................................................................................................................................... alpha-Methylthiofentanyl .............................................................................................................................................................. alpha-Methyltryptamine (AMT) .................................................................................................................................................... alpha-Pyrrolidinobutiophenone (a-PBP) ...................................................................................................................................... alpha-Pyrrolidinopentiophenone (a-PVP) .................................................................................................................................... Aminorex ...................................................................................................................................................................................... Benzylmorphine ........................................................................................................................................................................... Betacetylmethadol ....................................................................................................................................................................... beta-Hydroxy-3-methylfentanyl .................................................................................................................................................... beta-Hydroxyfentanyl ................................................................................................................................................................... Betameprodine ............................................................................................................................................................................. Betamethadol ............................................................................................................................................................................... Betaprodine .................................................................................................................................................................................. Bufotenine .................................................................................................................................................................................... Cathinone ..................................................................................................................................................................................... Codeine methylbromide ............................................................................................................................................................... Codeine-N-oxide .......................................................................................................................................................................... Desomorphine .............................................................................................................................................................................. Diethyltryptamine ......................................................................................................................................................................... Difenoxin ...................................................................................................................................................................................... Dihydromorphine .......................................................................................................................................................................... Dimethyltryptamine ...................................................................................................................................................................... Dipipanone ................................................................................................................................................................................... Fenethylline .................................................................................................................................................................................. gamma-Hydroxybutyric acid ........................................................................................................................................................ Heroin .......................................................................................................................................................................................... Hydromorphinol ............................................................................................................................................................................ Hydroxypethidine ......................................................................................................................................................................... Ibogaine ....................................................................................................................................................................................... Lysergic acid diethylamide (LSD) ................................................................................................................................................ Marihuana .................................................................................................................................................................................... Mescaline ..................................................................................................................................................................................... Methaqualone .............................................................................................................................................................................. Methcathinone ............................................................................................................................................................................. Methyldesorphine ......................................................................................................................................................................... VerDate Mar<15>2010 15:14 Sep 05, 2014 Jkt 232001 PO 00000 Frm 00057 Fmt 4703 Sfmt 4703 E:\FR\FM\08SEN1.SGM 08SEN1 15 15 25 25 25 30 30 25 55 50 40 50 35 15 2 2 25 25 15 100 25 25 15 45 15 68 53 25 25 25 2 2 2 2 2 25 2 2 2 2 25 15 15 25 2 2 2 2 2 4 2 3 70 5 305 5 25 50 3,990,000 35 5 5 70,250,000 25 2 2 5 35 125,000 25 10 25 5 Federal Register / Vol. 79, No. 173 / Monday, September 8, 2014 / Notices 53219 Established 2015 quotas (g) Basic class Methyldihydromorphine ................................................................................................................................................................ Morphine methylbromide ............................................................................................................................................................. Morphine methylsulfonate ............................................................................................................................................................ Morphine-N-oxide ........................................................................................................................................................................ N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide (AKB48) ................................................................................................ N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (ADB-PINACA) ............................................. N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA) .................................. N,N-Dimethylamphetamine .......................................................................................................................................................... Naphthylpyrovalerone (naphyrone) ............................................................................................................................................. N-Benzylpiperazine ...................................................................................................................................................................... N-Ethyl-1-phenylcyclohexylamine ................................................................................................................................................ N-Ethylamphetamine ................................................................................................................................................................... N-Hydroxy-3,4-methylenedioxyamphetamine .............................................................................................................................. Noracymethadol ........................................................................................................................................................................... Norlevorphanol ............................................................................................................................................................................. Normethadone ............................................................................................................................................................................. Normorphine ................................................................................................................................................................................ Phenomorphan ............................................................................................................................................................................ Psilocybin ..................................................................................................................................................................................... Psilocyn ........................................................................................................................................................................................ Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5-fluoro-PB-22; 5F-PB-22) ................................................................ Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-22; QUPIC) ................................................................................................ Tetrahydrocannabinols ................................................................................................................................................................ Thiofentanyl ................................................................................................................................................................................. Tilidine .......................................................................................................................................................................................... Trimeperidine ............................................................................................................................................................................... 2 5 5 350 15 15 15 25 15 25 5 24 24 2 52 2 18 2 30 30 15 15 497,500 2 10 2 Schedule II rmajette on DSK2TPTVN1PROD with NOTICES 1-Phenylcyclohexylamine ............................................................................................................................................................ 1-Piperidinocyclohexanecarbonitrile ............................................................................................................................................ 4-Anilino-N-phenethyl-4-piperidine (ANPP) ................................................................................................................................. Alfentanil ...................................................................................................................................................................................... Alphaprodine ................................................................................................................................................................................ Amobarbital .................................................................................................................................................................................. Amphetamine (for conversion) .................................................................................................................................................... Amphetamine (for sale) ............................................................................................................................................................... Carfentanil .................................................................................................................................................................................... Cocaine ........................................................................................................................................................................................ Codeine (for conversion) ............................................................................................................................................................. Codeine (for sale) ........................................................................................................................................................................ Dextropropoxyphene .................................................................................................................................................................... Dihydrocodeine ............................................................................................................................................................................ Diphenoxylate .............................................................................................................................................................................. Ecgonine ...................................................................................................................................................................................... Ethylmorphine .............................................................................................................................................................................. Fentanyl ....................................................................................................................................................................................... Glutethimide ................................................................................................................................................................................. Hydrocodone (for conversion) ..................................................................................................................................................... Hydrocodone (for sale) ................................................................................................................................................................ Hydromorphone ........................................................................................................................................................................... Isomethadone .............................................................................................................................................................................. Levo-alphacetylmethadol (LAAM) ................................................................................................................................................ Levomethorphan .......................................................................................................................................................................... Levorphanol ................................................................................................................................................................................. Lisdexamfetamine ........................................................................................................................................................................ Meperidine ................................................................................................................................................................................... Meperidine Intermediate-A .......................................................................................................................................................... Meperidine Intermediate-B .......................................................................................................................................................... Meperidine Intermediate-C .......................................................................................................................................................... Metazocine ................................................................................................................................................................................... Methadone (for sale) ................................................................................................................................................................... Methadone Intermediate .............................................................................................................................................................. Methamphetamine ....................................................................................................................................................................... 5 5 2,687,500 17,750 3 25,125 21,875,000 37,500,000 19 275,000 50,000,000 49,500,000 19 226,375 1,337,500 174,375 3 2,150,000 3 137,500 99,625,000 7,000,000 5 4 5 7,125 29,750,000 6,250,000 6 11 6 19 31,875,000 34,375,000 2,061,375 [1,250,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 750,000 grams for methamphetamine mostly for conversion to a schedule III product; and 61,375 grams for methamphetamine (for sale)] Methylphenidate ........................................................................................................................................................................... Morphine (for conversion) ............................................................................................................................................................ Morphine (for sale) ...................................................................................................................................................................... Nabilone ....................................................................................................................................................................................... Noroxymorphone (for conversion) ............................................................................................................................................... VerDate Mar<15>2010 15:14 Sep 05, 2014 Jkt 232001 PO 00000 Frm 00058 Fmt 4703 Sfmt 4703 E:\FR\FM\08SEN1.SGM 08SEN1 83,750,000 91,250,000 62,500,000 18,750 17,500,000 53220 Federal Register / Vol. 79, No. 173 / Monday, September 8, 2014 / Notices Established 2015 quotas (g) Basic class Noroxymorphone (for sale) .......................................................................................................................................................... Opium (powder) ........................................................................................................................................................................... Opium (tincture) ........................................................................................................................................................................... Oripavine ...................................................................................................................................................................................... Oxycodone (for conversion) ........................................................................................................................................................ Oxycodone (for sale) ................................................................................................................................................................... Oxymorphone (for conversion) .................................................................................................................................................... Oxymorphone (for sale) ............................................................................................................................................................... Pentobarbital ................................................................................................................................................................................ Phenazocine ................................................................................................................................................................................ Phencyclidine ............................................................................................................................................................................... Phenmetrazine ............................................................................................................................................................................. Phenylacetone ............................................................................................................................................................................. Racemethorphan ......................................................................................................................................................................... Remifentanil ................................................................................................................................................................................. Secobarbital ................................................................................................................................................................................. Sufentanil ..................................................................................................................................................................................... Tapentadol ................................................................................................................................................................................... Thebaine ...................................................................................................................................................................................... 1,475,000 112,500 687,500 35,000,000 8,350,000 137,500,000 29,000,000 7,750,000 35,000,000 6 19 3 9,375,000 3 3,750 215,003 6,255 12,500,000 125,000,000 List I Chemicals Ephedrine (for conversion) .......................................................................................................................................................... Ephedrine (for sale) ..................................................................................................................................................................... Phenylpropanolamine (for conversion) ........................................................................................................................................ Phenylpropanolamine (for sale) ................................................................................................................................................... Pseudoephedrine (for conversion) .............................................................................................................................................. Pseudoephedrine (for sale) ......................................................................................................................................................... The Deputy Administrator also establishes aggregate production quotas for all other schedule I and II controlled substances included in 21 CFR 1308.11 and 1308.12 at zero. In accordance with 21 CFR 1303.13 and 21 CFR 1315.13, upon consideration of the relevant factors, the Deputy Administrator may adjust the 2015 aggregate production quotas and assessment of annual needs as needed. Dated: September 2, 2014. Thomas M. Harrigan, Deputy Administrator. [FR Doc. 2014–21280 Filed 9–5–14; 8:45 am] BILLING CODE 4410–09–P OFFICE OF SCIENCE AND TECHNOLOGY POLICY National Nanotechnology Coordination Office Nanoscale Science, Engineering, and Technology Subcommittee; Committee on Technology, National Science and Technology Council; Meeting rmajette on DSK2TPTVN1PROD with NOTICES ACTION: Notice of public meeting. The National Nanotechnology Coordination Office (NNCO), on behalf of the Nanoscale Science, Engineering, and Technology (NSET) Subcommittee of the Committee on Technology, National Science and Technology Council (NSTC), will hold a technical SUMMARY: VerDate Mar<15>2010 15:14 Sep 05, 2014 Jkt 232001 interchange meeting entitled ‘‘Realizing the Promise of Carbon Nanotubes— Challenges, Opportunities and the Pathway to Commercialization’’ on September 15, 2014. The meeting will be sponsored by the National Nanotechnology Initiative (NNI) and cosponsored by the National Aeronautics and Space Administration (NASA). The objectives of this meeting are to identify, discuss, and report the technical barriers preventing the production of carbon nanotube-based materials with electrical and mechanical properties approaching theoretical values, and to explore ways to overcome these barriers. Obstacles preventing the full exploitation of the multifunctional nature of carbon nanotube materials will also be discussed. This one-day meeting will assemble some of the Nation’s leading experts in carbon nanotube research and development, as well as executives and experts from the Federal government, academia, and private sector. The technical interchange meeting will be held Monday, September 15, 2014 from 8:00 a.m. until 5:15 p.m. ADDRESSES: The technical interchange meeting will be held at the National Aeronautics and Space Administration (NASA) Headquarters, 300 E Street Southwest, Washington, DC 20546. FOR FURTHER INFORMATION, CONTACT: Dr. Tarek Fadel, 703–292–7926, tfadel@ DATES: PO 00000 Frm 00059 Fmt 4703 Sfmt 9990 1,000,000 4,000,000 44,800,000 8,500,000 7,000 224,500,000 nnco.nano.gov, NNCO. Additional information is posted at: http:// nano.gov/2014CNTTechInterchange. Registration: Registration opens on September 8, 2014. Due to space limitations, pre-registration for the technical interchange meeting is required. Written notices of participation by email should be sent to dpetreski@nnco.nano.gov or mailed to Diana Petreski, 4201 Wilson Blvd., Stafford II, Suite 405, Arlington, VA 22230. Please provide your full name, title, affiliation and email or mailing address when registering. Registration is on a first-come, first-served basis until capacity is reached. Written or electronic comments should be submitted by email to dpetreski@ nnco.nano.gov until close of business September 10, 2014. Meeting Accommodations: Individuals requiring special accommodation to access this meeting should contact Diana Petreski at 703– 292–7922 at least five business days prior to the meeting so that appropriate arrangements can be made. Ted Wackler, Deputy Chief of Staff and Assistant Director. [FR Doc. 2014–21201 Filed 9–5–14; 8:45 am] BILLING CODE P E:\FR\FM\08SEN1.SGM 08SEN1

Agencies

[Federal Register Volume 79, Number 173 (Monday, September 8, 2014)]
[Notices]
[Pages 53216-53220]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-21280]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-393]


Established Aggregate Production Quotas for Schedule I and II 
Controlled Substances and Assessment of Annual Needs for the List I 
Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2015

AGENCY: Drug Enforcement Administration (DEA), Department of Justice 
(DOJ).

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This notice establishes the initial 2015 aggregate production 
quotas for controlled substances in schedules I and II of the 
Controlled Substances Act (CSA) and the assessment of annual needs for 
the list I chemicals ephedrine, pseudoephedrine, and 
phenylpropanolamine.

DATES: Effective date: Effective September 8, 2014.

FOR FURTHER INFORMATION CONTACT: Imelda Paredes, Executive Assistant, 
Office of Diversion Control, Drug Enforcement Administration, 8701 
Morrissette Drive, Springfield, VA 22152, Telephone: (202) 598-6812.

SUPPLEMENTARY INFORMATION:

Legal Authority

    The Drug Enforcement Administration (DEA) implements and enforces 
titles II and III of the Comprehensive Drug Abuse Prevention and 
Control Act of 1970, as amended. Titles II and III are referred to as 
the ``Controlled Substances Act'' and the ``Controlled Substances 
Import and Export Act,'' respectively, and are collectively referred to 
as the ``Controlled Substances Act'' or the ``CSA'' for the purpose of 
this action. 21 U.S.C. 801-971. The DEA publishes the implementing 
regulations for these statutes in title 21 of the Code of Federal 
Regulations (CFR), parts 1300 to 1321. The CSA and its implementing 
regulations are designed to prevent, detect, and eliminate the 
diversion of controlled substances and listed chemicals into the 
illicit market while providing for the legitimate medical, scientific, 
research, and industrial needs of the United States. Controlled 
substances have the potential for abuse and dependence and are 
controlled to protect the public health and safety.
    Section 306 of the Controlled Substances Act (CSA) (21 U.S.C. 826) 
requires the Attorney General to establish aggregate production quotas 
for each basic class of controlled substance listed in schedules I and 
II and for ephedrine, pseudoephedrine, and phenylpropanolamine. This 
responsibility has been delegated to the Administrator of the DEA 
through 28 CFR 0.100(b). The Administrator, in turn, has redelegated 
this function to the Deputy Administrator, pursuant to 28 CFR pt. 0 
subpt. R, App.

Background

    The 2015 aggregate production quotas and assessment of annual needs 
represent those quantities of schedule I and II controlled substances 
and the list I chemicals ephedrine, pseudoephedrine, and 
phenylpropanolamine to be manufactured in the United States in 2015 to 
provide for the estimated medical, scientific, research, and industrial 
needs of the United States, lawful export requirements, and the 
establishment and maintenance of reserve stocks. These quotas include 
imports of ephedrine, pseudoephedrine, and phenylpropanolamine but do 
not include imports of controlled substances for use in industrial 
processes.
    On July 2, 2014, a notice titled, ``Proposed Aggregate Production 
Quotas for Schedule I and II Controlled Substances and Proposed 
Assessment of Annual Needs for the List I Chemicals Ephedrine, 
Pseudoephedrine, and Phenylpropanolamine for 2015'' was published in 
the Federal Register. 79 FR 37772. This notice proposed the 2015 
aggregate production quotas for each basic class of controlled 
substance listed in schedules I and II and the 2015 assessment of 
annual needs for the list I chemicals ephedrine, pseudoephedrine, and 
phenylpropanolamine. All interested persons were invited to comment on 
or object to the proposed aggregate production quotas and the proposed 
assessment of annual needs on or before August 1, 2014.

Comments Received

    Five comments were received from DEA-registered manufacturers 
within the published comment period, offering comments on a total of 32 
schedule I and II controlled substances. None of the respondents 
commented on the list I chemicals ephedrine, pseudoephedrine, and 
phenylpropanolamine. Commenters stated that the proposed aggregate 
production quotas for 1-(1,3-Benzodioxol-5-yl)-2-(methylamino) butan-1-
one (butylone), 1-(1,3-Benzodioxol-5-yl)-2-(methylamino) pentan-1-one 
(pentylone), 2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-
methoxybenzyl)ethanamine (25B-NBOMe), 2-(4-Chloro-2,5-dimethoxyphenyl)-
N-(2-methoxybenzyl)ethanamine (25C-NBOMe), 2-(4-Iodo-2,5-
dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe), 2-
(Methylamino)-1-phenylpentan-1-one (pentedrone), 3-Fluoro-N-
methylcathinone (3-FMC), 4-Fluoro-N-methylcathinone (4-FMC), 4-Anilino-
N-phenethyl-4-piperidine (ANPP), 4-Methyl-N-ethylcathinone (4-MEC), 4-
Methyl-[alpha]-pyrrolidinopropiophenone (4-MePPP), alpha-
Pyrrolidinobutiophenone ([alpha]-PBP), alpha-Pyrrolidinopentiophenone 
([alpha]-PVP), amphetamine (for sale), codeine (for sale), 
dihydrocodeine, diphenoxylate, fentanyl, hydrocodone (for sale), 
hydromorphone, levorphanol, marihuana, morphine (for conversion), N-(1-
Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide 
(ADB-PINACA), N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-
1H-indazole-3-carboxamide (AB-FUBINACA), naphthylpyrovalerone 
(naphyrone), oripavine, oxycodone (for conversion), oxymorphone (for 
conversion), oxymorphone (for sale), Quinolin-8-yl 1-(5-fluoropentyl)-
1H-indole-3-carboxylate (5-Flouro-PB-22), and Quinolin-8-yl 1-pentyl-
1H-indole-3-carboxylate (PB-22) were insufficient to provide for the 
estimated medical, scientific, research, and industrial needs of the 
United States, export requirements, and the establishment and 
maintenance of reserve stocks.

Determination of 2015 Aggregate Production Quotas and Assessment of 
Annual Needs

    In determining the 2015 aggregate production quotas and assessment 
of annual needs, the DEA has taken into consideration the above 
comments along with the factors set forth at 21 CFR 1303.11 and 21 CFR 
1315.11, in accordance with 21 U.S.C. 826 (a), and other relevant 
factors, including the consideration of 2014 manufacturing quotas, 
current 2014 sales and inventories, 2015 export requirements, 
industrial use, additional applications for quotas, as well as 
information on research and product development requirements. Based on 
this information, the DEA has determined

[[Page 53217]]

that adjustments to the proposed aggregate production quotas and 
assessment of annual needs for alfentanil, cocaine, codeine-N-oxide, 
codeine (for sale), dihydrocodeine, fentanyl, hydromorphone, 
levorphanol, marihuana, oripavine, oxymorphone (for conversion), and 
ephedrine (for sale) are warranted. This notice reflects those 
adjustments.
    Regarding 1-(1,3-Benzodioxol-5-yl)-2-(methylamino)butan-1-one 
(butylone), 1-(1,3-Benzodioxol-5-yl)-2-(methylamino)pentan-1-one 
(pentylone), 2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-
methoxybenzyl)ethanamine (25B-NBOMe), 2-(4-Chloro-2,5-dimethoxyphenyl)-
N-(2-methoxybenzyl)ethanamine (25C-NBOMe), 2-(4-Iodo-2,5-
dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe), 2-
(Methylamino)-1-phenylpentan-1-one (pentedrone), 3-Fluoro-N-
methylcathinone (3-FMC), 4-Fluoro-N-methylcathinone (4-FMC), 4-Anilino-
N-phenethyl-4-piperidine (ANPP), 4-Methyl-N-ethylcathinone (4-MEC), 4-
Methyl-[alpha]-pyrrolidinopropiophenone (4-MePPP), alpha-
Pyrrolidinobutiophenone ([alpha]-PBP), alpha-Pyrrolidinopentiophenone 
([alpha]-PVP), amphetamine (for sale), dihydrocodeine, fentanyl, 
hydromorphone, levorphanol, marihuana, N-(1-Amino-3,3-dimethyl-1-
oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (ADB-PINACA), N-(1-
Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-
carboxamide (AB-FUBINACA), naphthylpyrovalerone (naphyrone), oxycodone 
(for conversion), oxymorphone (for sale), Quinolin-8-yl 1-(5-
fluoropentyl)-1H-indole-3-carboxylate (5-Flouro-PB-22), and Quinolin-8-
yl 1-pentyl-1H-indole-3-carboxylate (PB-22), the DEA has determined 
that the proposed aggregate production quotas are sufficient to provide 
for the 2015 estimated medical, scientific, research, and industrial 
needs of the United States, export requirements, and the establishment 
and maintenance of reserve stocks. This notice finalizes these 
aggregate production quotas at the same amounts as proposed.
    As described in the previously published notice proposing the 2015 
aggregate production quotas and assessment of annual needs, the DEA has 
specifically considered that inventory allowances granted to individual 
manufacturers may not always result in the availability of sufficient 
quantities to maintain an adequate reserve stock pursuant to 21 U.S.C. 
826(a), as intended. See 21 CFR 1303.24. This would be concerning if a 
natural disaster or other unforeseen event resulted in substantial 
disruption to the amount of controlled substances available to provide 
for legitimate public need. As such, the DEA has included in all 
established schedule II aggregate production quotas, and certain 
schedule I aggregate production quotas, an additional 25% of the 
estimated medical, scientific, and research needs as part of the amount 
necessary to ensure the establishment and maintenance of reserve 
stocks. The resulting established aggregate production quota will 
reflect these included amounts. This action will not affect the ability 
of manufacturers to maintain inventory allowances as specified by 
regulation. The DEA expects that maintaining this reserve in certain 
established aggregate production quotas will mitigate adverse public 
effects if an unforeseen event results in the substantial disruption to 
the amount of controlled substances available to provide for legitimate 
public need, as determined by the DEA. The DEA does not anticipate 
utilizing the reserve in the absence of these circumstances.
    In accordance with 21 U.S.C. 826, 21 CFR 1303.11, and 21 CFR 
1315.11, the Deputy Administrator hereby establishes the 2015 aggregate 
production quotas for the following schedule I and II controlled 
substances and the 2015 assessment of annual needs for the list I 
chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, 
expressed in grams of anhydrous acid or base, as follows:

------------------------------------------------------------------------
                                                       Established 2015
                     Basic class                          quotas (g)
------------------------------------------------------------------------
                               Schedule I
------------------------------------------------------------------------
(1-Pentyl-1H-indol-3-yl)(2,2,3,3-                                     15
 tetramethylcyclopropyl)methanone (UR-144)..........
[1-(5-Fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-                          15
 tetramethylcyclopropyl)methanone (XLR11)...........
1-(1,3-Benzodioxol-5-yl)-2-(methylamino)butan-1-one                   15
 (butylone).........................................
1-(1,3-Benzodioxol-5-yl)-2-(methylamino)pentan-1-one                  15
 (pentylone)........................................
1-(1-Phenylcyclohexyl)pyrrolidine...................                  10
1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201)...                  45
1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694)..                  45
1-[1-(2-Thienyl)cyclohexyl]piperidine...............                  15
1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole                      45
 (JWH-200)..........................................
1-Butyl-3-(1-naphthoyl)indole (JWH-073).............                  45
1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole                     45
 (SR-18 and RCS-8)..................................
1-Hexyl-3-(1-naphthoyl)indole (JWH-019).............                  45
1-Methyl-4-phenyl-4-propionoxypiperidine............                   2
1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM678)..                  45
1-Pentyl-3-(2-chlorophenylacetyl)indole (JWH-203)...                  45
1-Pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250)..                  45
1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398)...                  45
1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122)...                  45
1-Pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19, RCS-                   45
 4).................................................
1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081).                  45
2-(2,5-Dimethoxy-4-n-propylphenyl)ethanamine (2C-P).                  30
2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E)....                  30
2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D)...                  30
2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N)...                  30
2-(2,5-Dimethoxyphenyl)ethanamine (2C-H)............                  30
2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-                                 15
 methoxybenzyl)ethanamine (25B-NBOMe; 2C-B-NBOMe;
 25B; Cimbi-36).....................................
2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C)...                  30
2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-                                15
 methoxybenzyl)ethanamine (25C-NBOMe; 2C-C-NBOMe;
 25C; Cimbi-82).....................................
2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I).....                  30

[[Page 53218]]

 
2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-                                  15
 methoxybenzyl)ethanamine (25I-NBOMe; 2C-I-NBOMe;
 25I; Cimbi-5)......................................
2-(Methylamino)-1-phenylpentan-1-one (pentedrone)...                  15
2,5-Dimethoxy-4-ethylamphetamine (DOET).............                  25
2,5-Dimethoxy-4-n-propylthiophenethylamine..........                  25
2,5-Dimethoxyamphetamine............................                  25
2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-                  30
 T-2)...............................................
2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine                   30
 (2C-T-4)...........................................
3,4,5-Trimethoxyamphetamine.........................                  25
3,4-Methylenedioxyamphetamine (MDA).................                  55
3,4-Methylenedioxymethamphetamine (MDMA)............                  50
3,4-Methylenedioxy-N-ethylamphetamine (MDEA)........                  40
3,4-Methylenedioxy-N-methylcathinone (methylone)....                  50
3,4-Methylenedioxypyrovalerone (MDPV)...............                  35
3-Fluoro-N-methylcathinone (3-FMC)..................                  15
3-Methylfentanyl....................................                   2
3-Methylthiofentanyl................................                   2
4-Bromo-2,5-dimethoxyamphetamine (DOB)..............                  25
4-Bromo-2,5-dimethoxyphenethylamine (2-CB)..........                  25
4-Fluoro-N-methylcathinone (4-FMC)..................                  15
4-Methoxyamphetamine................................                 100
4-Methyl-2,5-dimethoxyamphetamine (DOM).............                  25
4-Methylaminorex....................................                  25
4-Methyl-N-ethylcathinone (4-MEC)...................                  15
4-Methyl-N-methylcathinone (mephedrone).............                  45
4-Methyl-[alpha]-pyrrolidinopropiophenone (4-MePPP).                  15
5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-                                  68
 hydroxycyclohexyl]-phenol..........................
5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-                                   53
 hydroxycyclohexyl]-phenol (cannabicyclohexanol or
 CP-47,497 C8-homolog)..............................
5-Methoxy-3,4-methylenedioxyamphetamine.............                  25
5-Methoxy-N,N-diisopropyltryptamine.................                  25
5-Methoxy-N,N-dimethyltryptamine....................                  25
Acetyl-alpha-methylfentanyl.........................                   2
Acetyldihydrocodeine................................                   2
Acetylmethadol......................................                   2
Allylprodine........................................                   2
Alphacetylmethadol..................................                   2
alpha-Ethyltryptamine...............................                  25
Alphameprodine......................................                   2
Alphamethadol.......................................                   2
alpha-Methylfentanyl................................                   2
alpha-Methylthiofentanyl............................                   2
alpha-Methyltryptamine (AMT)........................                  25
alpha-Pyrrolidinobutiophenone ([alpha]-PBP).........                  15
alpha-Pyrrolidinopentiophenone ([alpha]-PVP)........                  15
Aminorex............................................                  25
Benzylmorphine......................................                   2
Betacetylmethadol...................................                   2
beta-Hydroxy-3-methylfentanyl.......................                   2
beta-Hydroxyfentanyl................................                   2
Betameprodine.......................................                   2
Betamethadol........................................                   4
Betaprodine.........................................                   2
Bufotenine..........................................                   3
Cathinone...........................................                  70
Codeine methylbromide...............................                   5
Codeine-N-oxide.....................................                 305
Desomorphine........................................                   5
Diethyltryptamine...................................                  25
Difenoxin...........................................                  50
Dihydromorphine.....................................           3,990,000
Dimethyltryptamine..................................                  35
Dipipanone..........................................                   5
Fenethylline........................................                   5
gamma-Hydroxybutyric acid...........................          70,250,000
Heroin..............................................                  25
Hydromorphinol......................................                   2
Hydroxypethidine....................................                   2
Ibogaine............................................                   5
Lysergic acid diethylamide (LSD)....................                  35
Marihuana...........................................             125,000
Mescaline...........................................                  25
Methaqualone........................................                  10
Methcathinone.......................................                  25
Methyldesorphine....................................                   5

[[Page 53219]]

 
Methyldihydromorphine...............................                   2
Morphine methylbromide..............................                   5
Morphine methylsulfonate............................                   5
Morphine-N-oxide....................................                 350
N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide                    15
 (AKB48)............................................
N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-                 15
 indazole-3-carboxamide (ADB-PINACA)................
N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-                            15
 fluorobenzyl)-1H-indazole-3-carboxamide (AB-
 FUBINACA)..........................................
N,N-Dimethylamphetamine.............................                  25
Naphthylpyrovalerone (naphyrone)....................                  15
N-Benzylpiperazine..................................                  25
N-Ethyl-1-phenylcyclohexylamine.....................                   5
N-Ethylamphetamine..................................                  24
N-Hydroxy-3,4-methylenedioxyamphetamine.............                  24
Noracymethadol......................................                   2
Norlevorphanol......................................                  52
Normethadone........................................                   2
Normorphine.........................................                  18
Phenomorphan........................................                   2
Psilocybin..........................................                  30
Psilocyn............................................                  30
Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-                         15
 carboxylate (5-fluoro-PB-22; 5F-PB-22).............
Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-                   15
 22; QUPIC).........................................
Tetrahydrocannabinols...............................             497,500
Thiofentanyl........................................                   2
Tilidine............................................                  10
Trimeperidine.......................................                   2
------------------------------------------------------------------------
                               Schedule II
------------------------------------------------------------------------
1-Phenylcyclohexylamine.............................                   5
1-Piperidinocyclohexanecarbonitrile.................                   5
4-Anilino-N-phenethyl-4-piperidine (ANPP)...........           2,687,500
Alfentanil..........................................              17,750
Alphaprodine........................................                   3
Amobarbital.........................................              25,125
Amphetamine (for conversion)........................          21,875,000
Amphetamine (for sale)..............................          37,500,000
Carfentanil.........................................                  19
Cocaine.............................................             275,000
Codeine (for conversion)............................          50,000,000
Codeine (for sale)..................................          49,500,000
Dextropropoxyphene..................................                  19
Dihydrocodeine......................................             226,375
Diphenoxylate.......................................           1,337,500
Ecgonine............................................             174,375
Ethylmorphine.......................................                   3
Fentanyl............................................           2,150,000
Glutethimide........................................                   3
Hydrocodone (for conversion)........................             137,500
Hydrocodone (for sale)..............................          99,625,000
Hydromorphone.......................................           7,000,000
Isomethadone........................................                   5
Levo-alphacetylmethadol (LAAM)......................                   4
Levomethorphan......................................                   5
Levorphanol.........................................               7,125
Lisdexamfetamine....................................          29,750,000
Meperidine..........................................           6,250,000
Meperidine Intermediate-A...........................                   6
Meperidine Intermediate-B...........................                  11
Meperidine Intermediate-C...........................                   6
Metazocine..........................................                  19
Methadone (for sale)................................          31,875,000
Methadone Intermediate..............................          34,375,000
Methamphetamine.....................................           2,061,375
------------------------------------------------------------------------
[1,250,000 grams of levo-desoxyephedrine for use in a non-controlled,
 non-prescription product; 750,000 grams for methamphetamine mostly for
 conversion to a schedule III product; and 61,375 grams for
 methamphetamine (for sale)]
------------------------------------------------------------------------
Methylphenidate.....................................          83,750,000
Morphine (for conversion)...........................          91,250,000
Morphine (for sale).................................          62,500,000
Nabilone............................................              18,750
Noroxymorphone (for conversion).....................          17,500,000

[[Page 53220]]

 
Noroxymorphone (for sale)...........................           1,475,000
Opium (powder)......................................             112,500
Opium (tincture)....................................             687,500
Oripavine...........................................          35,000,000
Oxycodone (for conversion)..........................           8,350,000
Oxycodone (for sale)................................         137,500,000
Oxymorphone (for conversion)........................          29,000,000
Oxymorphone (for sale)..............................           7,750,000
Pentobarbital.......................................          35,000,000
Phenazocine.........................................                   6
Phencyclidine.......................................                  19
Phenmetrazine.......................................                   3
Phenylacetone.......................................           9,375,000
Racemethorphan......................................                   3
Remifentanil........................................               3,750
Secobarbital........................................             215,003
Sufentanil..........................................               6,255
Tapentadol..........................................          12,500,000
Thebaine............................................         125,000,000
------------------------------------------------------------------------
                            List I Chemicals
------------------------------------------------------------------------
Ephedrine (for conversion)..........................           1,000,000
Ephedrine (for sale)................................           4,000,000
Phenylpropanolamine (for conversion)................          44,800,000
Phenylpropanolamine (for sale)......................           8,500,000
Pseudoephedrine (for conversion)....................               7,000
Pseudoephedrine (for sale)..........................         224,500,000
------------------------------------------------------------------------

    The Deputy Administrator also establishes aggregate production 
quotas for all other schedule I and II controlled substances included 
in 21 CFR 1308.11 and 1308.12 at zero. In accordance with 21 CFR 
1303.13 and 21 CFR 1315.13, upon consideration of the relevant factors, 
the Deputy Administrator may adjust the 2015 aggregate production 
quotas and assessment of annual needs as needed.

    Dated: September 2, 2014.
Thomas M. Harrigan,
Deputy Administrator.
[FR Doc. 2014-21280 Filed 9-5-14; 8:45 am]
BILLING CODE 4410-09-P